Phio Pharmaceuticals Corp. - Common Stock — 분기별 재무 통계 (NASDAQ:PHIO)

Financials

영업활동으로 인한 현금 -1.37 M-1.27 M-2.54 M-2.08 M-2.08 M-4 M -10.71 M 투자 활동으로 인한 현금 8 000-2 000-3 000-7 00003 000 -7 000 재무활동으로 인한 현금 1.35 M9.17 M40 K2.02 M12.4 M0 14.47 M 잉여 현금 흐름 -1.37 M-1.27 M-2.54 M-2.09 M-2.08 M-4 M -10.72 M

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.

PHIO

Financials

Phio Pharmaceuticals Corp. - Common Stock

뉴스

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Phio Pharma (NASDAQ:PHIO)

피오 파마슈티컬 주가, 강력한 암 치료 결과에 급등

Phio Pharmaceuticals stock soars after strong cancer treatment results

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Phio Pharma (NASDAQ:PHIO)

피오 파마슈티컬, 피부암 임상시험서 70% 반응률 보고

Phio Pharmaceuticals reports 70% response rate in skin cancer trial

Phio 제약 회장 비터만, 5,100달러 상당 주식 매수

Phio, FDA 요구 독성 연구 개시 (암 치료제 PH-762)

Phio to begin FDA-required toxicology study for cancer drug PH-762

Phio, 피부암 치료제 1b상 임상 등록 완료

Phio completes enrollment in Phase 1b trial of skin cancer therapy

피오, INTASYL PH-762, 올해의 면역조절 솔루션 수상